New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
17:08 EDTBDSI, ENDPBioDelivery Sciences reports cash at end of FY12 $63.2M vs. $10.8M
BioDelivery Sciences (BDSI) ,BDSI's, research and development expenditures increased from $20.8M in 2011 to $35.4M in 2012. Revenues recognized in 2012 were $54.5M, including $35.8M from Endo (ENDP) and $17.5M previously deferred revenue associated with the BDSI commercialization agreement with Meda for BDSI's FDA approved product ONSOLIS. At the end of 2012, BDSI had $9.2M in deferred revenue associated with Endo, which will be recognized through 2013 and into early 2014 as clinical trials progress. BDSI reported net income of $1.7M or 5c per share for the twelve months ending December 31. That compares to a net loss of $23.3M or (82c) per share in 2011. At the end of 2012, BDSI had $63.2M in cash compared to $10.8M at December 31, 2011.
News For BDSI;ENDP From The Last 14 Days
Check below for free stories on BDSI;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
10:02 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:42 EDTENDPEndo initiated with an Outperform at RBC Capital
Subscribe for More Information
August 25, 2014
09:26 EDTENDPEndo puts AMS medical-device unit up for sale, WSJ says
Subscribe for More Information
August 22, 2014
09:38 EDTBDSIBioDelivery Sciences sales may jump on DEA move, says Summer Street
Subscribe for More Information
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use